Dr. Reem Al-Essa has a PhD in Pharmaceutical Regulations, MBA General and Strategic Management, MSc in PV and Pharmacoepidemiology, MSc Health Economics and Pharmacoeconomics and BSc. Pharmacy (Honours), with a long and diversified experience in both government and private sectors in Kuwait.

She started her career in Kuwait Ministry of Health, Drug and Food Control, Pharmaceutical and Herbal Medicines Registration and Control Administration, holding the position of Drug Registration Superintendent. She was appointed in the position of Coordination and Development Superintendent at the Pharmaceutical Services Administration and then became the Director of Drug Inspection Administration (DIA) in addition to holding her role as a Pharmacovigilance Superintendent in Kuwait Office for Pharmacovigilance Surveillance (KOPS).

Dr. Mona Al Moussli is a trailblazer in the field of pharmaceutical and medical device regulatory affairs in the Middle East. With over twenty years of experience, she has firmly established herself as a seasoned professional renowned for her unparalleled expertise in navigating the intricacies of healthcare regulations

Throughout her career, Dr. Al Moussli has demonstrated an unwavering dedication to upholding the highest standards of ethics and compliance within the industry. In 2013, she co-founded PRA Consultancy, a firm that has since become synonymous with regulatory excellence in the region.

Her impact transcends traditional boardroom boundaries as she actively works to shape the future of healthcare regulation through education and advocacy. Notably, Dr. Al Moussli played a pivotal role in the inception of the GCC Regulatory Affairs (RA) Course, a pioneering certification program designed to nurture the next generation of industry experts.
Fueled by her passion for advancing health and safety standards, Dr. Al Moussli has spearheaded numerous initiatives, including the renowned GCC Regulatory Affairs Pharma Summit and other significant gatherings focused on pharmaceutical-related regulations in the region.

Dr. Al Moussli’s commitment to advancing regulatory standards transcends borders, as evidenced by her initiation of the AFRI Summit. This crucial platform facilitates discussions on pharmaceutical and medical device regulations in Africa, fostering knowledge sharing and collaboration among stakeholders to improve healthcare outcomes across the continent.
Beyond her professional achievements, Dr. Al Moussli remains actively involved in community engagement, serving as an advisory board member at Dubai Pharmacy College and lending her expertise to the Women’s Business Council at the Dubai Chamber of Commerce. In recognition of her outstanding contributions, Dr. Mona Al Moussli was elected as a board member of the Emirates Medical Association – Pharmacy chapter for consecutive terms in 2021 and 2022.

Dr. Katya Nabeel Ailabouni is a Clinical Pharmacist with extensive experience in the UAE Ministry of Health. She holds an M. Pharm. in Clinical Pharmacy (2024, Al Ain University, UAE) and a B.Sc. in Pharmacy (1999, Philadelphia University, Amman, Jordan).

Since 2004, Dr. Katya has worked with the Ministry of Health’s Registration and Drug Control Department. From 2005-2008, she served as a Registration Officer, handling New Drug Applications, renewals, and manufacturing facility registrations. Since 2008, she has been a Pharmacovigilance Officer and a reporter for the UAE National Pharmacovigilance Committee.

Earlier in her career, Dr. Katya was the Pharmacist-in-Charge at Al Nahdha Pharmacy, Abu Dhabi (2002-2003), and a Pharmacist at Mermaid Pharmacy, Abu Dhabi (1999-2001).

She is a qualified professional with 7 years of experience in the Drug Department, having worked across multiple functions, including the regulation of Narcotics, Psychotropics, and Precursor Chemicals. Her expertise extends to conducting GMP audits both locally and internationally, monitoring drug quality and safety, and investigating malpractice within the industry, all with a focus on ensuring the safe use of medicines across the country.

She has played a pivotal role in strengthening MOHAP’s partnerships with other federal entities, including the Ministry of Interior, the Federal Customs Authority, and the Weapons and Hazardous Substances Office, as well as collaborating with international organizations such as the World Health Organization (WHO) and the International Narcotics Control Board (INCB).